Estrella Immunopharma (ESLA) Competitors $1.14 0.00 (0.00%) As of 03:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ESLA vs. PBYI, CYBN, ACRS, NLTX, ADCT, FATE, RAPT, FULC, GLSI, and EDITShould you be buying Estrella Immunopharma stock or one of its competitors? The main competitors of Estrella Immunopharma include Puma Biotechnology (PBYI), Cybin (CYBN), Aclaris Therapeutics (ACRS), Neoleukin Therapeutics (NLTX), ADC Therapeutics (ADCT), Fate Therapeutics (FATE), RAPT Therapeutics (RAPT), Fulcrum Therapeutics (FULC), Greenwich LifeSciences (GLSI), and Editas Medicine (EDIT). These companies are all part of the "pharmaceutical products" industry. Estrella Immunopharma vs. Puma Biotechnology Cybin Aclaris Therapeutics Neoleukin Therapeutics ADC Therapeutics Fate Therapeutics RAPT Therapeutics Fulcrum Therapeutics Greenwich LifeSciences Editas Medicine Puma Biotechnology (NASDAQ:PBYI) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, community ranking, media sentiment and profitability. Do analysts recommend PBYI or ESLA? Puma Biotechnology presently has a consensus target price of $7.00, indicating a potential upside of 117.05%. Estrella Immunopharma has a consensus target price of $16.00, indicating a potential upside of 1,280.50%. Given Estrella Immunopharma's higher probable upside, analysts clearly believe Estrella Immunopharma is more favorable than Puma Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Estrella Immunopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, PBYI or ESLA? Puma Biotechnology has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, Estrella Immunopharma has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. Does the media prefer PBYI or ESLA? In the previous week, Puma Biotechnology had 7 more articles in the media than Estrella Immunopharma. MarketBeat recorded 9 mentions for Puma Biotechnology and 2 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 1.44 beat Puma Biotechnology's score of 0.75 indicating that Estrella Immunopharma is being referred to more favorably in the news media. Company Overall Sentiment Puma Biotechnology Positive Estrella Immunopharma Positive Which has higher earnings & valuation, PBYI or ESLA? Puma Biotechnology has higher revenue and earnings than Estrella Immunopharma. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPuma Biotechnology$230.47M0.69$21.59M$0.615.29Estrella ImmunopharmaN/AN/A-$7.31M-$0.26-4.46 Do insiders and institutionals have more ownership in PBYI or ESLA? 61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 0.3% of Estrella Immunopharma shares are held by institutional investors. 23.7% of Puma Biotechnology shares are held by company insiders. Comparatively, 55.1% of Estrella Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is PBYI or ESLA more profitable? Puma Biotechnology has a net margin of 9.56% compared to Estrella Immunopharma's net margin of 0.00%. Puma Biotechnology's return on equity of 41.60% beat Estrella Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets Puma Biotechnology9.56% 41.60% 10.71% Estrella Immunopharma N/A -195.77%-157.28% Does the MarketBeat Community favor PBYI or ESLA? Puma Biotechnology received 555 more outperform votes than Estrella Immunopharma when rated by MarketBeat users. However, 100.00% of users gave Estrella Immunopharma an outperform vote while only 67.31% of users gave Puma Biotechnology an outperform vote. CompanyUnderperformOutperformPuma BiotechnologyOutperform Votes55667.31% Underperform Votes27032.69% Estrella ImmunopharmaOutperform Votes1100.00% Underperform VotesNo Votes SummaryPuma Biotechnology beats Estrella Immunopharma on 11 of the 15 factors compared between the two stocks. Get Estrella Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ESLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESLA vs. The Competition Export to ExcelMetricEstrella ImmunopharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.92M$2.97B$5.54B$8.03BDividend YieldN/A1.87%5.09%4.22%P/E Ratio-4.4630.4522.7118.78Price / SalesN/A502.42407.35107.90Price / CashN/A168.6838.1834.62Price / Book9.663.226.804.34Net Income-$7.31M-$72.35M$3.22B$247.93M7 Day Performance15.90%4.26%2.16%2.60%1 Month Performance42.91%7.84%3.54%4.15%1 Year Performance10.17%-21.90%16.80%5.82% Estrella Immunopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESLAEstrella Immunopharma3.0462 of 5 stars$1.14flat$16.00+1,303.5%+8.6%$41.23MN/A-4.38N/APositive NewsGap UpPBYIPuma Biotechnology3.8353 of 5 stars$2.98-0.7%$7.00+134.9%-37.8%$147.84M$230.47M6.21200Upcoming EarningsAnalyst RevisionNews CoverageCYBNCybin2.0245 of 5 stars$6.87-1.7%$86.00+1,151.8%N/A$147.55MN/A-1.5750News CoverageACRSAclaris Therapeutics3.1776 of 5 stars$1.36+1.5%$11.67+757.8%+9.5%$147.26M$18.72M-2.62100Upcoming EarningsShort Interest ↓News CoveragePositive NewsNLTXNeoleukin TherapeuticsN/A$15.41+0.3%N/A-56.5%$144.82MN/A-4.9590High Trading VolumeADCTADC Therapeutics1.4199 of 5 stars$1.46+9.8%$7.75+430.8%-69.1%$144.81M$70.84M-0.61310Upcoming EarningsFATEFate Therapeutics3.7393 of 5 stars$1.25-2.3%$5.43+334.3%-69.7%$143.26M$13.63M-0.76550Upcoming EarningsNews CoverageRAPTRAPT Therapeutics4.1797 of 5 stars$0.92+4.8%$4.00+334.3%-88.8%$139.93M$1.53M-0.3380Upcoming EarningsShort Interest ↓News CoveragePositive NewsGap DownFULCFulcrum Therapeutics2.0168 of 5 stars$3.57+1.1%$8.63+141.6%-40.2%$135.49M$80M-11.52100Earnings ReportNews CoveragePositive NewsGLSIGreenwich LifeSciences1.8579 of 5 stars$10.04+0.6%$39.00+288.4%-28.7%$133.27MN/A-12.553Short Interest ↑EDITEditas Medicine4.1661 of 5 stars$1.58+2.6%$6.54+313.8%-70.4%$132.26M$32.31M-0.62230Upcoming EarningsAnalyst UpgradeAnalyst RevisionNews Coverage Related Companies and Tools Related Companies Puma Biotechnology Competitors Cybin Competitors Aclaris Therapeutics Competitors Neoleukin Therapeutics Competitors ADC Therapeutics Competitors Fate Therapeutics Competitors RAPT Therapeutics Competitors Fulcrum Therapeutics Competitors Greenwich LifeSciences Competitors Editas Medicine Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ESLA) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
